StocksMedium•4 November 2026•
1 min read
FDA Grants Priority Review to BeOne Medicines' BRUKINSA Combination
Key Facts
1The U.S. FDA accepted and granted Priority Review to the supplemental New Drug Application for BRUKINSA in combination with rituximab.
2The treatment targets adult patients with previously untreated mantle cell lymphoma (MCL).
The U.S. FDA accepted and granted Priority Review to the supplemental New Drug Application for BRUKINSA in combination with rituximab, Business Wire reported. The treatment targets adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by positive data from the pivotal Phase 3 MANGROVE clinical trial.
ONC closed at $355 on November 3, 2026, with the session seeing a day high of $357.54 and a day low of $347.61. This regulatory progress for BeOne Medicines coincides with broader U.S. economic updates, including JOLTs Job Openings reaching 7.523 million as of November 3, 2026.